Shenzhen Zhongge Biotechnology Co. Ltd. has disclosed translation initiation factor 2B (eIF2B) activators reported to be useful for the treatment of viral infections, inflammation, cancer, neurodegeneration, and autoimmune, eye, renal and dermatological disorders, among others.